Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
The Hartford announced that Christopher J. Swift will resign as CEO effective March 1, 2027, transitioning to the role of Executive Chair before retiring in late 2027. A. Morris Tooker, the company's current President, has been appointed to succeed Swift as CEO and will join the Board of Directors effective October 1, 2026. The Board approved a target total annual compensation opportunity for Mr. Tooker of $12 million effective upon his appointment as CEO.
Hormel Foods Signs $1.05B M&A Deal with Brakebush Brothers, LLC
Hormel Foods has entered into a definitive agreement to acquire Brakebush Brothers, LLC, a leading value-added chicken company, for $1.055 billion in cash. The acquisition is intended to strengthen Hormel's position in the growing chicken protein category and expand its foodservice segment capabilities. The transaction is expected to close in the first quarter of Hormel's fiscal 2027.
Zedge, Inc. completed a private placement of 2,616,447 shares of Class B common stock and warrants to purchase 2,354,803 shares, raising $7.675 million in gross proceeds. The investment was led by Vice Chairman Howard Jonas through Chartwell Holding LLC, with participation from board member Elliot Gibber. The company intends to use the capital to accelerate the growth of its B2B AI data business, DataSeeds.AI.
Hyperscale Data $21M Debt Financing with JGB Capital, LP
Hyperscale Data and its subsidiaries entered into an amendment to their existing loan agreement, facilitating an additional $21 million loan to affiliate Ault & Company. The amendment also extends the maturity date of all loans under the agreement to December 14, 2027, with the new debt secured by various company assets and mortgages.
ASP Isotopes Director Robert John Andrew Ryan Buys $21.6K of Stock
Robert John Andrew Ryan, Director, bought 8,000 shares of ASP Isotopes Inc. at $2.70 a share, worth $21.6K in total on Sep 28, 2026. Shares held after the trade: 660,222 (+1.2%).
Conduent is hosting an Investor Day in New York City to outline its 'ASCEND 2026-28' strategic framework, focusing on long-term growth, portfolio priorities, and cost reduction initiatives. The presentation includes financial targets through fiscal year 2028, including expectations for revenue growth, Adjusted EBITDA margins, and leverage reduction following the divestitures of its Transit and Tolling businesses.
Addentax Group Corp. entered into a private placement agreement with investor Chan Kai Sang to sell 520,834 shares of common stock at $4.80 per share. The transaction is expected to generate gross proceeds of approximately $2.5 million, which the company intends to use for general corporate purposes and strategic investments.
Sagimet Biosciences Deal Termination with Leerink Partners LLC
Sagimet Biosciences has suspended and terminated its at-the-market (ATM) offering prospectus supplement related to its Series A common stock. The company will not make any further sales under the sales agreement with Leerink Partners LLC until a new prospectus or registration statement is filed. The filing also included an updated investor presentation and clinical trial results for denifanstat in acne vulgaris.
Marygold Companies M&A Deal with Madison Dearborn Partners
The Marygold Companies provided a status update on its previously announced definitive merger agreement with Madison Dearborn Partners (MDP), where MDP will acquire all outstanding shares for $2.00 per share. The company confirmed that stockholders representing 75% of the voting power have already delivered written consent approving the deal, and as a result, the company is no longer permitted to pursue alternative acquisition proposals.
Cal-Maine Foods reported first quarter fiscal 2027 net sales of $539.6 million, a 41.5% decrease year-over-year, and a net loss of $58.6 million. The results were significantly impacted by a 59.3% decrease in average selling prices for conventional shell eggs due to an industry supply imbalance, despite growth in the Specialty Shell Eggs and Prepared Foods segments.
Term
Q1 2027
Earnings call
Sep 30, 2026, 9:00 AM ET
“Our first-quarter results reflect both the current point in the conventional shell egg cycle and the continued evolution of Cal-Maine Foods’ earnings model. Conventional Shell Egg pricing remains under pressure from an industry supply imbalance, while underlying demand remains healthy. At the same time, Specialty Shell Eggs and Prepared Foods now represent approximately 54% of our net sales, demonstrating the progress we have made in broadening our business. We remain focused on our foundational Conventional Shell Egg business while scaling Specialty and Prepared Foods and converting the investments we have made into profitable growth.”
Sherman Miller, president and chief executive officer of Cal-Maine Foods
OceanLight Acquisition Signs $1B M&A Deal with AIRE Inc.
OceanLight Acquisition Corporation (OCLT), a SPAC, has entered into a definitive merger agreement to acquire AIRE Inc., a home textile and green sleep technology company, at an enterprise value of $1.0 billion. Upon closing, the combined entity will be known as AIRE Global Group Inc. and is expected to remain listed on the Nasdaq. The transaction will involve the issuance of 100 million shares to AIRE shareholders at a value of $10.00 per share.
AeroVironment held its 2026 Annual Meeting of Stockholders where five directors were elected to one-year terms. Stockholders also ratified the selection of Deloitte & Touche LLP as independent auditors for fiscal year 2027 and approved executive compensation in an advisory vote.
Miniso Group Holding VP and CFO Jingjing Eason Zhang Buys $340K of Stock
Jingjing Eason Zhang, VP and CFO, bought 150,600 shares of Miniso Group Holding Ltd at $2.26 a share, worth $340K in total on Sep 29, 2026. Shares held after the trade: 394,474 (+61.8%).
Artificial Intelligence Technology Solutions Business Update
Artificial Intelligence Technology Solutions' subsidiary, RAD, received an additional order for one RIO 360 unit from an existing global healthcare technology client. This follows a previous order from the same customer earlier in the month and is intended for after-hours trespass deterrence at a second location.
DBV Technologies has submitted a Biologics License Application (BLA) to the U.S. FDA for its VIASKIN Peanut Patch for children aged 4-7 years. The submission is based on positive Phase 3 VITESSE trial results and marks the company's transition toward a commercial-stage organization. The company has requested Priority Review for the application.
Ares Management Corporation provided a preliminary estimate for its realized net performance income for the third quarter ending September 30, 2026. The company expects approximately $10 million in realized net performance income, a slight increase from the $9 million reported in the same period the prior year.
News Corp provided a daily update on its $1 billion stock repurchase program as required by Australian Securities Exchange (ASX) rules. The program authorizes the company to buy back outstanding shares of both Class A and Class B common stock from time to time in the open market. The filing includes specific daily transaction notifications for Class A common stock repurchases.
Invest Acquisition Corp shareholders approved an amendment to extend the company's business combination deadline from December 17, 2027, to December 17, 2029. In connection with the extension, holders of 1,801,349 Class A ordinary shares elected to redeem their shares for approximately $22.2 million from the trust account.
IB Acquisition Corp. (IBAC) held a special meeting where stockholders approved an extension to the deadline for completing its initial business combination from September 28, 2026, to March 28, 2027. The company filed a charter amendment to formalize this extension and updated its trust agreement to reflect the new liquidation and redemption timeline.
Barnes & Noble Education held its 2026 Annual Meeting of Stockholders on September 24, 2026, where shareholders elected six directors to the board. Stockholders also approved an amendment to the company's Equity Incentive Plan to increase the number of authorized shares, ratified the appointment of BDO USA, P.C. as independent auditors, and approved executive compensation on an advisory basis.
Reliance Global Group Divestiture to Altruis Benefit Management, LLC for $8M
Reliance Global Group's subsidiary, Altruis Benefit Consultants, sold substantially all assets of its employee benefits insurance agency business to Altruis Benefit Management, LLC for $8 million. The consideration consists of approximately $4.44 million in cash, a $3.1 million secured promissory note, and $461,729 in holdbacks, with potential earnout payments of up to $1 million based on future revenue growth. The transaction closed simultaneously with the signing of the asset purchase agreement on September 23, 2026.
Stonepeak-Plus Infrastructure Fund Capital Raise of $52.7M
Stonepeak-Plus Infrastructure Fund LP sold unregistered limited partnership units to third-party investors for approximately $52.7 million on September 1, 2026. The sale was part of a continuous private offering that has raised approximately $1.92 billion since its inception in May 2025.
Definium Therapeutics CFO Brandi Roberts Sells $123K of Stock
Brandi Roberts, CFO, sold 3,377 shares of Definium Therapeutics, Inc. at $36.57 a share, worth $123K in total on Sep 25, 2026. Shares held after the trade: 394,528 (-0.8%).
Definium Therapeutics CLO Mark Sullivan Sells $514K of Stock
Mark Sullivan, CLO, sold 14,051 shares of Definium Therapeutics, Inc. at $36.57 a share, worth $514K in total on Sep 25, 2026. Shares held after the trade: 494,228 (-2.8%).
Definium Therapeutics Chief Commercial Officer Matthew T. Wiley Sells $113K of Stock
Matthew T. Wiley, Chief Commercial Officer, sold 3,097 shares of Definium Therapeutics, Inc. at $36.57 a share, worth $113K in total on Sep 25, 2026. Shares held after the trade: 359,036 (-0.9%).
Definium Therapeutics CEO Robert Barrow Sells $1.15M of Stock
Robert Barrow, CEO, sold 31,550 shares of Definium Therapeutics, Inc. at $36.57 a share, worth $1.15M in total on Sep 25, 2026. Shares held after the trade: 2,213,090 (-1.4%).
Becton Dickinson & EVP, Chief Revenue Officer Michael Feld Sells $14K of Stock
Michael Feld, EVP, Chief Revenue Officer, sold 76 shares of Becton Dickinson & Co at $183.70 a share, worth $14K in total on Sep 28, 2026. Shares held after the trade: 19,644 (-0.4%).
Definium Therapeutics CMO Daniel Karlin Sells $397K of Stock
Daniel Karlin, CMO, sold 10,853 shares of Definium Therapeutics, Inc. at $36.57 a share, worth $397K in total on Sep 25, 2026. Shares held after the trade: 792,846 (-1.4%).
Photronics SVP & GM of FPD Ops Han Kyung Park Sells $289K of Stock
Han Kyung Park, SVP & GM of FPD Ops, sold 9,500 shares of Photronics Inc at $30.37 a share, worth $289K in total on Sep 25, 2026. Shares held after the trade: 66,000 (-12.6%).
ADARx Pharmaceuticals Director Simeon George Buys $27.2M of Stock
Simeon George, Director, bought 1,600,000 shares of ADARx Pharmaceuticals, Inc. at $17.00 a share, worth $27.2M in total on Sep 28, 2026. Shares held after the trade: 592,593.